Calcium sensing receptor agon 
Welcome,         Profile    Billing    Logout  
 13 Companies  8 Products   8 Products   70 Diseases   31 Trials   2140 News 
29 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cinacalcet HCl / Generic mfg.
2005-004148-29: Cinacalcet: Eine Pilotstudie bei therapierefraktärem Hyperparathyroidismus niereninsuffizienter Patienten.

Ongoing
4
20
Europe
Mimpara-Cinacalcet
MUW, Division of nephrology
Bei therapierefraktärem Hyperparathyroidismus wird bei Patienten mit chronischer Niereninsuffizienz ein neues Kalzimimetikum (Mimpara) eingesetzt.
 
 
2008-005055-23: TREATMENT OF HYPERPARATHYROIDISM IN PATIENTS WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 (MEN1) WITH THE CALCIMIMETIC AGENT CINACALCET

Ongoing
4
60
Europe
Tablet
OSPEDALE MAGGIORE DI MILANO (IRCCS)
Primary hyperparathyroidism in patients affected with multiple endocrine neoplasia syndrome type 1 (MEN1)
 
 
2009-009502-79: open, non comparative, prospectic, phase IV clinical study to evaluate the activity and tolerance of Cinacalcet-HCl (drug name Mimpara) in patients affected by MEN1-associated primary hyperparathyroidism

Ongoing
4
33
Europe
Film-coated tablet, MIMPARA
AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI
Primary hyperparathyroidism in patients with MEN1
 
 
2005-003871-19: A randomised control trial to identify the effects of cinacalcet on bone and cardiovascular health in end-stage renal disease

Ongoing
4
40
Europe
Tablet
Salford Royal Hospital
Secondary hyperparathyroidism in renal failure
 
 
2010-018861-53: Efficacy and safety of the calcimimetic Cinacalcet in the management of patients with Primary Hyperparathyroidism due to a MEN-1 mutation

Ongoing
4
20
Europe
Mimpara, Cinacalcet, Mimpara ®, Mimpara ®
Leiden University Medical Center
Patients with primary hyperparathyroidism due to a germline mutation in the MEN-1 gene
 
 
2009-015723-90: VARIATION OF PARATHYROID GLAND FOLLOWING CINACALCET USE IN DIALISYS PATIENTS WITH SONOGRAPHIC EVIDENCE OF SECONDARY HYPERPLASIA

Ongoing
4
70
Europe
MIMPARA*28CPR RIV 30MG, MIMPARA*28CPR RIV 60MG, MIMPARA*28CPR RIV 90MG, MIMPARA*28CPR RIV 30MG, MIMPARA*28CPR RIV 60MG, MIMPARA*28CPR RIV 90MG
AZIENDA OSPEDALIERA PISANA
secondary hyperparathyroidism
 
 
2010-021465-72: Ensayo clínico unicéntrico, abierto, no controlado, para determinar la variación en la concentración plasmática de hormona paratiroidea (PTH) en las 48 horas subsiguientes a la administración de cinacalcet en pacientes con hiperparatiroidismo secundario estable en tratamiento crónico con este fármaco.

Ongoing
4
10
Europe
MIMPARA 30 mg comprimidos recubiertos con película, MIMPARA 60 mg comprimidos recubiertos con película, MIMPARA 90 mg comprimidos recubiertos con película, MIMPARA 30 mg comprimidos recubiertos con película, MIMPARA 60 mg comprimidos recubiertos con película, MIMPARA 90 mg comprimidos recubiertos con película
Dra. Mª Dolores Arenas
Hiperparatiroidismo secundario estable
 
 
2010-021041-42: Use of Calcimimetics vs oral Paricalcitol in Renal transplant Patients affected with Persistent Secondary Hyperparathyroidism. A pilot study

Ongoing
4
16
Europe
ZEMPLAR, MIMPARA, ZEMPLAR, MIMPARA
AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
Renal transplant patients
 
 
2013-002270-52: Assess the stability / benefit of Cinacalcet treatment over conventional therapy based on bone metabolism, arterial stiffness and vascular calcification in advanced chronic renal failure evaluar la estabilidad/beneficio del tratamiento con Cinacalcet sobre el tratamiento convencional en base al metabolismo óseo, la rigidez arterial y la calcificación vascular en la insuficiencia renal crónicaavanzada.

Ongoing
4
80
Europe
Cinacalcet, Rocaltrol, Fosrenol, Cinacalcet, Rocaltrol, Fosrenol
Hospital Universitari de Girona Dr.Josep Trueta, Hospital Universitari de Girona Dr.Josep Trueta
Bone\'s disorders and mineral metabolism and vascular involvement trastornos del metabolismo óseo y mineral y la afectación vascular
 
 
ACTIVE Study, ChiCTR-OIC-17011089: Efficacy & safety of Cinacalcet HCL in Ca, P and iPTH levels in Chinese CKD Hemodialysis patients with mild, moderate and severe SHPT

Recruiting
4
750
 
Administer Cinacalet HCL tablet to subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL tablet from 33rd to 52nd week. ;Administer Cinacalet HCL tablet to subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL tablet from 33rd to 52nd week. ;Administer Cinacalet HCL tablet to subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL tablet from 33rd to 52nd week.
Nanjing Jinling Hospital; Kyowa Hakko Kirin (China) Pharmaceutic Co., LTD, Self Funding
Secondary Hyperparathyroidism (SHPT)
 
 
ChiCTR1900020610: Contrast-enhanced Ultrasound (CEUS) Manifestation and Histopathological Basis of Parathyroid Glands in Haemodialysis Patients with Secondary Hyperparathyroidism (SHPT) after Cinacalcet Therapy

Not yet recruiting
4
80
 
Cinacalcet ;No
China-Japan Friendship Hospital; China-Japan Friendship Hospital, Beijing Municipal Science & Technology Commission (Z181100001718135)
secondary hyperparathyroidism
 
 
ChiCTR1900026679: The influences of paclitaxel, calcitriol and cinacalcet on hemodialysis patients with CKD-MBD in real-world

Not yet recruiting
4
1000
 
take paricalcitol according to the condition ;take calcitriol according to the condition ;take cinacalcet according to the condition
Changzhou second people's Hospital; Changzhou Second People's Hospital, self-raised
chronic kidney disease-mineral and bone disorder
 
 
NCT05926570: Parathyroid Hormone Level and Growth in Pediatric Patients With ESRD on Regular Hemodialysis

Completed
4
35
RoW
Cinacalcet, Mimpara
Tanta University
Drug Effect
01/24
01/24
Osteo-Men, NCT03994172: Novel Combination Therapy for Osteoporosis in Men

Active, not recruiting
4
40
US
Teriparatide or human parathyroid hormone (PTH) 1-34, Forteo, Cinacalcet, Sensipar, placebo tablet, placebo, Calcium citrate tablet, Calcium citrate supplement, Vitamin D3, Cholecalciferol
VA Office of Research and Development, University of California, San Francisco
Male Osteoporosis
06/25
06/26
ChiCTR2000031420: Paricalcitol for treatment of secondary hyperparathyroidism in hemodialysis patients——a multicenter, randomized, positive controlled study

Not yet recruiting
4
242
 
Paricalcitol ;Cinacalcet
The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Secondary hyperparathyroidism in hemodialysis patients
 
 
ChiCTR2500099025: The Impact of Correcting Nutritional Vitamin D Deficiency and Bone Mineral Metabolism Disorders on Complications in Hemodialysis

Not yet recruiting
4
84
 
Correcting hyperphosphatemia with calcium containing or non calcium containing phosphate binders, and controlling secondary hyperparathyroidism with cinacalcet hydrochloride or paricalcitriol for a total of 12 months; On the basis of traditional treatment, an additional 800IU of vitamin D3 capsules were taken orally daily, and 60mg of denosumab was injected subcutaneously every 6 months for a total of 12 months
The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital); The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital)
Uremia Maintenance Hemodialysis
 
 
2007-002534-11: EFFICACITE D’UN TRAITEMENT PAR CINACALCET SUR LE METABOLISME OSSEUX CHEZ LES TRANSPLANTES RENAUX AVEC HYPERPARATHYROIDIE PERSISTANTE

Ongoing
3
10
Europe
MIMPARA, MIMPARA, MIMPARA
CHU de Caen
LES TRANSPLANTES RENAUX AVEC HYPERPARATHYROIDIE PERSISTANTE
 
 
SHR6508-301, NCT06434961: The Trial of SHR6508 in Secondary Hyperparathyroidism

Recruiting
3
486
RoW
SHR6508 plus oral placebo tablets, Cinacalcet plus intravenous placebo
Shanghai Hengrui Pharmaceutical Co., Ltd.
Secondary Hyperparathyroidism
06/25
07/25
NCT05663411: A Study of SHR6508 in Secondary Hyperparathyroidism

Active, not recruiting
2
75
RoW
SHR6508, Cinacalcet
Shanghai Hengrui Pharmaceutical Co., Ltd.
Secondary Hyperparathyroidism
10/23
11/23
NCT06288451: DePTH: De-emphasize PTH

Recruiting
2
90
US
Oral calcitriol with cinacalcet rescue, IV activated vitamin D
University of Washington, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Kidney Failure, Chronic, Chronic Kidney Disease-Mineral and Bone Disorder
02/27
02/27
CALCI-CINA, NCT04126954: Study on the Use of Cinacalcet in Phosphocalcic Context.

Not yet recruiting
N/A
25
Europe
Serum PTH concentrations results
Hospices Civils de Lyon
Hyperparathyroidism, Secondary, Hyperparathyroidism, Primary
01/21
12/23
Parsabiv (etelcalcetide) / Amgen
2017-000222-35: The effect of the drug etelcalcetide on heart muscle enlargement in hemodialysis patients - a randomized, controlled trial Effekt von dem Medikament Etelcalcetide auf die Herzmuskelvergrößerung in Hämodialysepatienten - eine randomizierte, kontrollierte Studie

Ongoing
4
62
Europe
Etelcalcetide, Alfacalcidol, Injection, Parsabiv, Etalpha
Medical University of Vienna, Amgen Europe B.V.
Secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis therapy. Sekundärer Hyperparathyreoidismus in erwachsenen Patientinnen und Patienten mit chronischer Niereninsuffizienz unter Hämodialysetherapie., Bone mineral disorder which occurs in patients with chronic kidney disease and require renal replacement therapy in the form of hemodialysis. Knochenstoffwechselerkrankung welche bei Patientinnen und Patienten mit chronischer Niereninsuffizienz auftritt, welche ein Nierenersatzverfahren in Form einer Hämodialyse benötigen., Diseases [C] - Hormonal diseases [C19]
 
 
NCT03969329 / 2018-004608-21: A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

Recruiting
3
24
Europe, RoW
Etelcalcetide, Parsabiv - brand name
Amgen
Secondary Hyperparathyroidism
06/25
06/25
NCT03633708 / 2017-002411-34: A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

Recruiting
3
56
US, RoW
Etelcalcetide, Parsabiv
Amgen
Secondary Hyperparathyroidism, Chronic Kidney Disease
01/27
01/27
CKD-1: KAI-4169 phase 2 trial for for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis

Ongoing
2
0
RoW
KAI-4169
Amgen
NOS
 
 
2018-000421-31: A study to investigate the influence of lowering PTH values in blood using medication called Etelcalcetide (Parsabiv®) on Calcification Preopensity of the blood in Patients with dialysis therapy.

Not yet recruiting
2
20
Europe
Parsabiv, Solution for injection, Parsabiv®, Parsabiv
Ordensklinikum Linz GmbH, ELISABETHINEN, Interne 3, AMGEN LIMITED
End stage renal disease, renal failure, Not possible to specify
 
 
Parsabiv-MBD, NCT03960437: The Effect of Etelcalcetide on CKD-MBD

Completed
2
22
US
Etelcalcetide, Parsabiv
Thomas Nickolas, MD MS
Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Vascular Calcification, Hyperparathyroidism; Secondary, Renal
11/20
11/20
NCT06690242: MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease

Recruiting
2
112
RoW
MT1013, Etelcalcetide Hydrochloride, Placebo
Shaanxi Micot Technology Limited Company
Secondary Hyperparathyroidism (SHPT) in Subjects with Chronic Kidney Disease (CKD) on Hemodialysis
08/25
03/26
ETERNITY-ITA, NCT06352957: Use of ETElcalcetidefor pReserving vitamiN K-dependent proteIn activiTY ITAlian Study

Not yet recruiting
N/A
160
NA
Istituto di Fisiologia Clinica CNR
Hemodialysis
12/26
12/27
ASP7991 / Astellas
No trials found
Orkedia (evocalcet) / Mitsubishi Tanabe
No trials found
NPSP-795 / Takeda
No trials found
REGPARA / Kyowa Kirin
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cinacalcet HCl / Generic mfg.
2005-004148-29: Cinacalcet: Eine Pilotstudie bei therapierefraktärem Hyperparathyroidismus niereninsuffizienter Patienten.

Ongoing
4
20
Europe
Mimpara-Cinacalcet
MUW, Division of nephrology
Bei therapierefraktärem Hyperparathyroidismus wird bei Patienten mit chronischer Niereninsuffizienz ein neues Kalzimimetikum (Mimpara) eingesetzt.
 
 
2008-005055-23: TREATMENT OF HYPERPARATHYROIDISM IN PATIENTS WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 (MEN1) WITH THE CALCIMIMETIC AGENT CINACALCET

Ongoing
4
60
Europe
Tablet
OSPEDALE MAGGIORE DI MILANO (IRCCS)
Primary hyperparathyroidism in patients affected with multiple endocrine neoplasia syndrome type 1 (MEN1)
 
 
2009-009502-79: open, non comparative, prospectic, phase IV clinical study to evaluate the activity and tolerance of Cinacalcet-HCl (drug name Mimpara) in patients affected by MEN1-associated primary hyperparathyroidism

Ongoing
4
33
Europe
Film-coated tablet, MIMPARA
AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI
Primary hyperparathyroidism in patients with MEN1
 
 
2005-003871-19: A randomised control trial to identify the effects of cinacalcet on bone and cardiovascular health in end-stage renal disease

Ongoing
4
40
Europe
Tablet
Salford Royal Hospital
Secondary hyperparathyroidism in renal failure
 
 
2010-018861-53: Efficacy and safety of the calcimimetic Cinacalcet in the management of patients with Primary Hyperparathyroidism due to a MEN-1 mutation

Ongoing
4
20
Europe
Mimpara, Cinacalcet, Mimpara ®, Mimpara ®
Leiden University Medical Center
Patients with primary hyperparathyroidism due to a germline mutation in the MEN-1 gene
 
 
2009-015723-90: VARIATION OF PARATHYROID GLAND FOLLOWING CINACALCET USE IN DIALISYS PATIENTS WITH SONOGRAPHIC EVIDENCE OF SECONDARY HYPERPLASIA

Ongoing
4
70
Europe
MIMPARA*28CPR RIV 30MG, MIMPARA*28CPR RIV 60MG, MIMPARA*28CPR RIV 90MG, MIMPARA*28CPR RIV 30MG, MIMPARA*28CPR RIV 60MG, MIMPARA*28CPR RIV 90MG
AZIENDA OSPEDALIERA PISANA
secondary hyperparathyroidism
 
 
2010-021465-72: Ensayo clínico unicéntrico, abierto, no controlado, para determinar la variación en la concentración plasmática de hormona paratiroidea (PTH) en las 48 horas subsiguientes a la administración de cinacalcet en pacientes con hiperparatiroidismo secundario estable en tratamiento crónico con este fármaco.

Ongoing
4
10
Europe
MIMPARA 30 mg comprimidos recubiertos con película, MIMPARA 60 mg comprimidos recubiertos con película, MIMPARA 90 mg comprimidos recubiertos con película, MIMPARA 30 mg comprimidos recubiertos con película, MIMPARA 60 mg comprimidos recubiertos con película, MIMPARA 90 mg comprimidos recubiertos con película
Dra. Mª Dolores Arenas
Hiperparatiroidismo secundario estable
 
 
2010-021041-42: Use of Calcimimetics vs oral Paricalcitol in Renal transplant Patients affected with Persistent Secondary Hyperparathyroidism. A pilot study

Ongoing
4
16
Europe
ZEMPLAR, MIMPARA, ZEMPLAR, MIMPARA
AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
Renal transplant patients
 
 
2013-002270-52: Assess the stability / benefit of Cinacalcet treatment over conventional therapy based on bone metabolism, arterial stiffness and vascular calcification in advanced chronic renal failure evaluar la estabilidad/beneficio del tratamiento con Cinacalcet sobre el tratamiento convencional en base al metabolismo óseo, la rigidez arterial y la calcificación vascular en la insuficiencia renal crónicaavanzada.

Ongoing
4
80
Europe
Cinacalcet, Rocaltrol, Fosrenol, Cinacalcet, Rocaltrol, Fosrenol
Hospital Universitari de Girona Dr.Josep Trueta, Hospital Universitari de Girona Dr.Josep Trueta
Bone\'s disorders and mineral metabolism and vascular involvement trastornos del metabolismo óseo y mineral y la afectación vascular
 
 
ACTIVE Study, ChiCTR-OIC-17011089: Efficacy & safety of Cinacalcet HCL in Ca, P and iPTH levels in Chinese CKD Hemodialysis patients with mild, moderate and severe SHPT

Recruiting
4
750
 
Administer Cinacalet HCL tablet to subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL tablet from 33rd to 52nd week. ;Administer Cinacalet HCL tablet to subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL tablet from 33rd to 52nd week. ;Administer Cinacalet HCL tablet to subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL tablet from 33rd to 52nd week.
Nanjing Jinling Hospital; Kyowa Hakko Kirin (China) Pharmaceutic Co., LTD, Self Funding
Secondary Hyperparathyroidism (SHPT)
 
 
ChiCTR1900020610: Contrast-enhanced Ultrasound (CEUS) Manifestation and Histopathological Basis of Parathyroid Glands in Haemodialysis Patients with Secondary Hyperparathyroidism (SHPT) after Cinacalcet Therapy

Not yet recruiting
4
80
 
Cinacalcet ;No
China-Japan Friendship Hospital; China-Japan Friendship Hospital, Beijing Municipal Science & Technology Commission (Z181100001718135)
secondary hyperparathyroidism
 
 
ChiCTR1900026679: The influences of paclitaxel, calcitriol and cinacalcet on hemodialysis patients with CKD-MBD in real-world

Not yet recruiting
4
1000
 
take paricalcitol according to the condition ;take calcitriol according to the condition ;take cinacalcet according to the condition
Changzhou second people's Hospital; Changzhou Second People's Hospital, self-raised
chronic kidney disease-mineral and bone disorder
 
 
NCT05926570: Parathyroid Hormone Level and Growth in Pediatric Patients With ESRD on Regular Hemodialysis

Completed
4
35
RoW
Cinacalcet, Mimpara
Tanta University
Drug Effect
01/24
01/24
Osteo-Men, NCT03994172: Novel Combination Therapy for Osteoporosis in Men

Active, not recruiting
4
40
US
Teriparatide or human parathyroid hormone (PTH) 1-34, Forteo, Cinacalcet, Sensipar, placebo tablet, placebo, Calcium citrate tablet, Calcium citrate supplement, Vitamin D3, Cholecalciferol
VA Office of Research and Development, University of California, San Francisco
Male Osteoporosis
06/25
06/26
ChiCTR2000031420: Paricalcitol for treatment of secondary hyperparathyroidism in hemodialysis patients——a multicenter, randomized, positive controlled study

Not yet recruiting
4
242
 
Paricalcitol ;Cinacalcet
The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Secondary hyperparathyroidism in hemodialysis patients
 
 
ChiCTR2500099025: The Impact of Correcting Nutritional Vitamin D Deficiency and Bone Mineral Metabolism Disorders on Complications in Hemodialysis

Not yet recruiting
4
84
 
Correcting hyperphosphatemia with calcium containing or non calcium containing phosphate binders, and controlling secondary hyperparathyroidism with cinacalcet hydrochloride or paricalcitriol for a total of 12 months; On the basis of traditional treatment, an additional 800IU of vitamin D3 capsules were taken orally daily, and 60mg of denosumab was injected subcutaneously every 6 months for a total of 12 months
The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital); The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital)
Uremia Maintenance Hemodialysis
 
 
2007-002534-11: EFFICACITE D’UN TRAITEMENT PAR CINACALCET SUR LE METABOLISME OSSEUX CHEZ LES TRANSPLANTES RENAUX AVEC HYPERPARATHYROIDIE PERSISTANTE

Ongoing
3
10
Europe
MIMPARA, MIMPARA, MIMPARA
CHU de Caen
LES TRANSPLANTES RENAUX AVEC HYPERPARATHYROIDIE PERSISTANTE
 
 
SHR6508-301, NCT06434961: The Trial of SHR6508 in Secondary Hyperparathyroidism

Recruiting
3
486
RoW
SHR6508 plus oral placebo tablets, Cinacalcet plus intravenous placebo
Shanghai Hengrui Pharmaceutical Co., Ltd.
Secondary Hyperparathyroidism
06/25
07/25
NCT05663411: A Study of SHR6508 in Secondary Hyperparathyroidism

Active, not recruiting
2
75
RoW
SHR6508, Cinacalcet
Shanghai Hengrui Pharmaceutical Co., Ltd.
Secondary Hyperparathyroidism
10/23
11/23
NCT06288451: DePTH: De-emphasize PTH

Recruiting
2
90
US
Oral calcitriol with cinacalcet rescue, IV activated vitamin D
University of Washington, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Kidney Failure, Chronic, Chronic Kidney Disease-Mineral and Bone Disorder
02/27
02/27
CALCI-CINA, NCT04126954: Study on the Use of Cinacalcet in Phosphocalcic Context.

Not yet recruiting
N/A
25
Europe
Serum PTH concentrations results
Hospices Civils de Lyon
Hyperparathyroidism, Secondary, Hyperparathyroidism, Primary
01/21
12/23
Parsabiv (etelcalcetide) / Amgen
2017-000222-35: The effect of the drug etelcalcetide on heart muscle enlargement in hemodialysis patients - a randomized, controlled trial Effekt von dem Medikament Etelcalcetide auf die Herzmuskelvergrößerung in Hämodialysepatienten - eine randomizierte, kontrollierte Studie

Ongoing
4
62
Europe
Etelcalcetide, Alfacalcidol, Injection, Parsabiv, Etalpha
Medical University of Vienna, Amgen Europe B.V.
Secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis therapy. Sekundärer Hyperparathyreoidismus in erwachsenen Patientinnen und Patienten mit chronischer Niereninsuffizienz unter Hämodialysetherapie., Bone mineral disorder which occurs in patients with chronic kidney disease and require renal replacement therapy in the form of hemodialysis. Knochenstoffwechselerkrankung welche bei Patientinnen und Patienten mit chronischer Niereninsuffizienz auftritt, welche ein Nierenersatzverfahren in Form einer Hämodialyse benötigen., Diseases [C] - Hormonal diseases [C19]
 
 
NCT03969329 / 2018-004608-21: A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

Recruiting
3
24
Europe, RoW
Etelcalcetide, Parsabiv - brand name
Amgen
Secondary Hyperparathyroidism
06/25
06/25
NCT03633708 / 2017-002411-34: A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

Recruiting
3
56
US, RoW
Etelcalcetide, Parsabiv
Amgen
Secondary Hyperparathyroidism, Chronic Kidney Disease
01/27
01/27
CKD-1: KAI-4169 phase 2 trial for for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis

Ongoing
2
0
RoW
KAI-4169
Amgen
NOS
 
 
2018-000421-31: A study to investigate the influence of lowering PTH values in blood using medication called Etelcalcetide (Parsabiv®) on Calcification Preopensity of the blood in Patients with dialysis therapy.

Not yet recruiting
2
20
Europe
Parsabiv, Solution for injection, Parsabiv®, Parsabiv
Ordensklinikum Linz GmbH, ELISABETHINEN, Interne 3, AMGEN LIMITED
End stage renal disease, renal failure, Not possible to specify
 
 
Parsabiv-MBD, NCT03960437: The Effect of Etelcalcetide on CKD-MBD

Completed
2
22
US
Etelcalcetide, Parsabiv
Thomas Nickolas, MD MS
Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Vascular Calcification, Hyperparathyroidism; Secondary, Renal
11/20
11/20
NCT06690242: MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease

Recruiting
2
112
RoW
MT1013, Etelcalcetide Hydrochloride, Placebo
Shaanxi Micot Technology Limited Company
Secondary Hyperparathyroidism (SHPT) in Subjects with Chronic Kidney Disease (CKD) on Hemodialysis
08/25
03/26
ETERNITY-ITA, NCT06352957: Use of ETElcalcetidefor pReserving vitamiN K-dependent proteIn activiTY ITAlian Study

Not yet recruiting
N/A
160
NA
Istituto di Fisiologia Clinica CNR
Hemodialysis
12/26
12/27
ASP7991 / Astellas
No trials found
Orkedia (evocalcet) / Mitsubishi Tanabe
No trials found
NPSP-795 / Takeda
No trials found
REGPARA / Kyowa Kirin
No trials found

Download Options